Latest Equity Financing News

TZ Limited has secured $0.50 million through a placement of 16.7 million shares at 3 cents each, using its 10% placement capacity, and is launching a 1-for-4 entitlement offer to raise an additional $2.58 million.

Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.

ACDC Metals closed its non-renounceable entitlement offer raising $348,000 from shareholders, but a substantial shortfall of over 24 million shares remains to be placed.

IperionX’s Definitive Feasibility Study for its Titan Project in Tennessee reveals a robust 14-year mine plan producing critical heavy rare earths, titanium minerals, and zircon with strong financial returns and US government backing.

Arafura Rare Earths has committed to constructing the Nolans Rare Earths Project, Australia's first fully integrated ore-to-oxide operation, backed by binding offtake deals and sovereign financing. Construction is slated to start in September 2026, positioning Nolans as a strategic node in global rare earth supply chains.

Legacy Minerals has withdrawn its earlier Mt Carrington production targets, updating its Scoping Study to reflect a stronger basis with 71% Indicated Resources. The revised study outlines a 12-year mine life, A$514 million pre-tax NPV7, and a streamlined development plan.

Vanadium Resources (ASX: VR8) has taken major steps to commercialise its Steelpoortdrift project with a non-binding offtake deal with U.S. Vanadium and appointed Rand Merchant Bank to lead funding efforts.

Accelerate Resources (ASX: AX8) has made significant strides in its dual-growth strategy, uncovering multiple gold mineralised corridors at Balagundi and defining a new high-grade manganese hub at Woodie Woodie North during the March 2026 quarter.

Vanadium Resources (ASX: VR8) has signed a non-binding offtake term sheet with U.S. Vanadium for 100% of vanadium slag from its Steelpoortdrift V-Iron Plant, while appointing Rand Merchant Bank to secure project financing.

Minerals 260 has locked in a $220 million funding deal with Franco-Nevada, combining royalty and equity financing to fast-track its 4.5Moz Bullabulling Gold Project. Strong drilling results and accelerated project work underpin a development timeline targeting first production by end 2028.

Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.

Kalamazoo Resources reported a robust cash balance of AUD 8.8 million at quarter end, underpinned by a significant equity raise that offsets ongoing exploration and administrative outflows. The company’s funding runway extends beyond three quarters, positioning it to advance its Ashburton Gold Project drilling activities.